Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with ...

Secukinumab rarely leads to latent tuberculosis infection as a reported adverse event and is supported for use in treating chronic systemic inflammatory conditions. TB is rare in the United States, ...

Please provide your email address to receive an email when new articles are posted on . Secukinumab is beneficial for patients with psoriatic arthritis across the spectrum of clinical phenotypes for ...

Patients with axial spondyloarthritis treated with secukinumab achieved a reduction in spinal pain and improved disease activity measures early in treatment. Secukinumab can effectively reduce spinal ...

In a recent trial, secukinumab -- a monoclonal anti-interleukin-17A antibody -- eased chronic itching in people with psoriasis. However, pruritus quickly recurred when secukinumab was switched to ...

Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or AS, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Secukinumab 300 mg is a safe and effective first-line ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Radiographic progression of structural joint ...

The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older ...

Adjusting MTX dose improves psoriasis response Data from two randomized trials demonstrate efficacy of secukinumab versus placebo. HealthDay News — For patients with moderate-to-severe plaque ...

Basel, September 25, 2014 - Novartis today announced that two pivotal Phase III studies (FUTURE 1 and FUTURE 2) of AIN457 (secukinumab) in psoriatic arthritis (PsA) met primary and key secondary ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of secukinumab, having considered evidence on the nature of ankylosing spondylitis (AS) and the value placed ...